Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

NASDAQ:KNSA   1:35:08 PM EDT
8.02
-0.12 (-1.47%)
Other Pre-Announcement

Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results, Provides Corporate Update

Published: 05/03/2022 12:50 GMT
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A (KNSA) - Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update.
Kiniksa Pharmaceuticals Ltd - Arcalyst (rilonacept) Net Revenue of $22.2 Million in Q1 2022.
Kiniksa Pharmaceuticals Ltd - Arcalyst Full-year 2022 Net Revenue Expected to Be $115 - $130 Million.
Kiniksa Pharmaceuticals Ltd - Cash Reserves Expected to Fund Operations Into at Least 2024.
Kiniksa Pharmaceuticals Ltd - Qtrly Net Loss per Share Attributable to Common Shareholders -basic and Diluted $0.36.